Clinical Study of Stent Versus Direct Atherectomy Versus Angioplasty to Treat Lower Limb In-stent Restenosis

Sponsor
Xuanwu Hospital, Beijing (Other)
Overall Status
Unknown status
CT.gov ID
NCT02832024
Collaborator
(none)
120
1
3
59
2

Study Details

Study Description

Brief Summary

This is a randomized study comparing Stent Versus Direct Atherectomy Versus Angioplasty to Treat Lower Limb In-stent Restenosis (superficial femoral or popliteal artery).

Condition or Disease Intervention/Treatment Phase
  • Device: plaque excision system
  • Device: stent
  • Device: Balloon
N/A

Detailed Description

This is a randomized study comparing Stent Versus Direct Atherectomy Versus Angioplasty to Treat Lower Limb In-stent Restenosis (superficial femoral or popliteal artery).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Study Start Date :
Jan 1, 2016
Anticipated Primary Completion Date :
Dec 1, 2019
Anticipated Study Completion Date :
Dec 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Intervention: Stents

Stents group

Device: stent

Active Comparator: Intervention: Atherectomy

Direct Atherectomy group

Device: plaque excision system

Active Comparator: Intervention: Balloon

Balloon group

Device: Balloon

Outcome Measures

Primary Outcome Measures

  1. Primary Patency Rate [12 months]

    Primary patency is defined as no significant reduction of flow detectable by Duplex ultrasound through the index lesion and no further clinically driven target vessel revascularization performed in the interim. Significant reduction of flow is binary restenosis defined as the diameter stenosis >50% with a peak systolic velocity ratio >2.4 as measured by Duplex ultrasound.

Secondary Outcome Measures

  1. Technical success [1 day]

    Technical success is defined as residual stenosis less than 30% by final angiography and/or a flow-limiting dissection.

  2. freedom from clinically-driven TLR [12 months]

    it is defined as freedom from clinically-driven target lesion revascularization

  3. Major Adverse Events [12 months]

    Major adverse events included death, index limb ischemia, index limb amputation, clinically driven target lesion revascularization, and significant embolic events, which were defined as causing end-organ damage.

  4. Limb Salvage Rate [12 months]

    Limb Salvage is defined as the freedom from secondary major amputation

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Provides written informed consent Willing to comply with follow-up evaluations at specified times Has claudication or rest pain due to peripheral arterial In-stent restenosis Disease located within the femoropopliteal artery Patient has a In-stent restenosis lesion(s) with

50% stenosis documented angiographically Patient has symptoms of peripheral arterial disease classified as Rutherford Category 2 or greater.

Exclusion Criteria:

They were excluded if they had one or more of the following: 1. Acute or subacute lower limb ischemia; 2. Severe calcification lesions; 3. Total occlusions lesions more significant than 10 cm or total occlusion lesions with a suspicion of subintimal wire recanalization 4. untreated ipsilateral iliac artery stenosis>70%, or the distal runoff artery <1 root; 5. Previously lower extremity intervention or surgical graft artery bypass; 6. Severe renal insufficiency, creatinine level greater than 2.5 mg/dL; 7. The patient's platelet count is less than 100,000/uL, antiplatelet or anticoagulant contraindications to required medications; 8. Patients with immune system diseases or malignant tumours; 9. ongoing active infection 10. decompensated congestive heart failure or acute coronary syndrome; 11. Unwillingness to return for future follow-up visits

Contacts and Locations

Locations

Site City State Country Postal Code
1 Gu Yong Quan Beijing Beijing China 100053

Sponsors and Collaborators

  • Xuanwu Hospital, Beijing

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Xuanwu Hospital, Beijing
ClinicalTrials.gov Identifier:
NCT02832024
Other Study ID Numbers:
  • WuanwuH
First Posted:
Jul 13, 2016
Last Update Posted:
Dec 4, 2019
Last Verified:
May 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Keywords provided by Xuanwu Hospital, Beijing
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 4, 2019